Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
6.30
-0.36 (-5.41%)
Feb 23, 2026, 4:00 PM EST - Market closed

Aptevo Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
6231137150
Market Cap Growth
185.74%-36.51%-68.79%-70.52%-75.46%460.07%
Enterprise Value
-10-0-10-14154
Last Close Price
6.301551.60106077.481359667.124612319.0521479224.05
PE Ratio
---1.36--
PS Ratio
---3.493.0034.89
PB Ratio
0.280.450.280.6130.349.06
P/TBV Ratio
0.360.450.280.6130.349.06
EV/Sales Ratio
----0.3435.68
Debt / Equity Ratio
0.281.140.440.5513.751.65
Net Debt / Equity Ratio
-0.94-0.70-0.94-0.70-23.30-0.76
Net Debt / EBITDA Ratio
0.620.140.410.461.400.48
Net Debt / FCF Ratio
0.620.140.980.601.260.43
Asset Turnover
---0.070.220.08
Quick Ratio
3.751.402.342.891.402.91
Current Ratio
4.031.722.643.151.513.25
Return on Equity (ROE)
-242.74%-284.28%-123.53%73.10%-330.24%-217.49%
Return on Assets (ROA)
-79.19%-76.06%-61.12%-39.42%-24.29%-32.13%
Return on Capital Employed (ROCE)
-124.90%-262.20%-163.90%-112.30%-98.00%-70.50%
Earnings Yield
-444.65%-1119.63%-512.92%73.80%-77.12%-11.80%
FCF Yield
-415.43%-1103.63%-345.56%-193.53%-60.69%-19.56%
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q